A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer

Healthy Volunteers Clinical Trial

Official title:

A Double-Blind, Placebo-Controlled, Randomized Clinical Pharmacology Study to Evaluate the Prevention Effect and the Recovery-Promoting Effect of a Single Subcutaneous Administration of GYM329 on Disuse Muscle Atrophy in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04708847
• Other study ID #: JP42791
• Status: Completed
• Phase: Phase 1
• Start date: February 10, 2021
• Est. completion date: February 1, 2023

Study information

• Verified date: February 2023
• Source: Chugai Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will induce disuse atrophy through unilateral immobilization of the thigh and lower leg in healthy male volunteers to evaluate the PD of a single subcutaneous dose of GYM329 prior to or after unilateral thigh and lower leg immobilization.

Healthy male volunteers will receive either GYM329 or placebo by subcutaneous injection at two time points, before and after 2 weeks of unilateral thigh and lower leg immobilization, in an investigator- and subject-blinded, randomized, placebo-controlled, parallel-group design. At enrollment, all subjects will be randomized in a 1:2 ratio to either the pre-immobilization active drug group receiving a single subcutaneous dose of GYM329 before unilateral thigh and lower leg immobilization (Group A) or the pre-immobilization placebo group receiving a single subcutaneous dose of placebo before unilateral thigh and lower leg immobilization (Group B). On Day 15, subjects assigned to Group B and who completed the muscle strength assessment at Day15 will be further randomized in a 1:1 ratio to either the post-immobilization active drug group (Group B-1) or the post-immobilization placebo group (Group B-2). Group A will receive GYM329 on Day 1 and placebo on Day 15. Group B will receive placebo on Day 1. Subsequently, Group B-1 will receive GYM329 on Day 15 and Group B-2 will receive placebo on Day 15.

Muscle strength will be measured at pre-immobilization of unilateral thigh and lower leg, post-immobilization of unilateral thigh and lower leg (Day 15), Day 29, and Day 43. Subjects will be observed for 252 days after the second study treatment administration (266 days after the first study treatment administration).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 1, 2023
• Est. primary completion date: June 3, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• Able and willing to provide written informed consent and to comply with the study protocol

• Healthy men aged from 18 to less than 40 years at the time of consent

• Right leg dominant

• Agreed to limit physical activity as directed by study site staff from the time of informed consent until the end of the muscle strength evaluation period (completion of Day 43)

• BMI is between 18.5 and less than 25.0 at screening

• Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.

Exclusion Criteria:

• History of congenital myopathy

• Congenital thrombophilia

• Previous or current VTE

• History of hip or limb surgery, spine or spinal cord surgery, or laparotomy (excluding laparotomy for appendicitis or inguinal hernia), or laparoscopic surgery (e.g. cholecystectomy)

• History of fracture of the pelvis or open/compound fracture of lower limb, or history of fracture within 3 years prior to screening, excluding digit fracture

• History of severe trauma, trauma requiring surgical intervention, or trauma with organ injury which deemed as clinically significant by the investigator

• Previous or current medical condition that could lead to thrombosis as judged by the investigator

• Angiography within 6 months before first study treatment administration

• Current Grade = 3 thermal burn or history of Grade = 3 thermal burn within 3 months prior to study treatment administration

• Unable to wear compression stockings

• History of heparin-induced thrombocytopenia or hypersensitivity to the LMWH and to the heparin or any other clinically significant contra-indications for use of LMWH

• Participation in bodybuilding or full time employment in a physically demanding occupation

• Immobilization, surgery, or traumatic injury of the arm within 90 days before first study treatment administration

• Traumatic injury of the leg within 6 months before first study treatment administration

• Immobilization or surgery of the leg within 6 months before first study treatment administration

• Immobilization of the leg for 2 or more weeks within 12 months before first study treatment administration

• Contraindication for MRI

• Habitual excessive over- or under-eating

• Any condition that may interfere with assessment of local pain and pruritus at the injection site

Related Conditions & MeSH terms

• Atrophy
• Healthy Volunteers
• Muscular Atrophy

Intervention

Drug:
• GYM329
GYM329 subcutaneous injection
• Placebo
Placebo subcutaneous injection

Locations

Country	Name	City	State
Netherlands	QPS Netherlands B.V.	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
Chugai Pharmaceutical

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Thigh muscle strength score	Percent change in thigh muscle strength score from Day 1 to Day 15 and Day 15 to Day 29 (Thigh muscle strength score: peak isometric knee extension torque and peak isokinetic knee extension torque at 90°/s and 180°/s)	28 days
Secondary	Safety; Adverse event monitoring	Incidence and severity of adverse events	45 weeks
Secondary	Safety; Laboratory tests	Incidence of laboratory abnormalities, based on clinical laboratory tests	45 weeks
Secondary	Safety; Vital signs	Abnormality in vital signs	45 weeks
Secondary	Safety; Electrocardiogram (ECG)	Abnormality in Electrocardiograms (ECGs)	45 weeks
Secondary	Pharmacokinetics; Serum GYM329 concentrations	Serum GYM329 concentrations over time	45 weeks
Secondary	Pharmacokinetics; Cmax	Cmax of GYM329	45 weeks
Secondary	Pharmacokinetics; Tmax	Tmax of GYM329	45 weeks
Secondary	Pharmacokinetics; AUC	AUC of GYM329	45 weeks
Secondary	Pharmacokinetics; T1/2	T1/2 of GYM329	45 weeks
Secondary	Immunogenicity	Incidence of serum anti-GYM329 antibodies	45 weeks
Secondary	Pharmacodynamics; Muscle volume	Changes in thigh muscle volume over time	45 weeks
Secondary	Pharmacodynamics; Total and free latent myostatin, mature myostatin	Changes in total and free latent myostatin, mature myostatin over time	45 weeks